- Report
- July 2024
- 202 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Report
- September 2022
- 152 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- October 2023
- 145 Pages
Global
From €2867EUR$3,150USD£2,458GBP
- Report
- June 2023
- 204 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Nalmefene is a drug used to treat addiction disorders, such as alcohol and opioid dependence. It is an opioid receptor antagonist, meaning it blocks the effects of opioids on the brain. It is taken orally and is available in both tablet and injection form. Nalmefene works by reducing cravings and decreasing the amount of alcohol consumed. It is also used to reduce the risk of relapse in those who have already stopped drinking.
Nalmefene is a relatively new drug, having been approved by the US Food and Drug Administration in 2014. It is currently available in many countries, including the United States, Canada, the United Kingdom, and Australia.
The market for nalmefene is growing, as more people are seeking treatment for addiction disorders. It is becoming increasingly popular as a treatment option due to its effectiveness and safety profile.
Some companies in the nalmefene market include Lundbeck, Orexo, and Indivior. Show Less Read more